FibroScan® Mini+ 430
Point-of-care mobile solution for hospital and office-based settings
- LSM by VCTE®
- CAP
- SSM by VCTE®
- LHM™ compatibility
- FibroScan® Gateway compatibility
- myFibroScan compatibility
- Ultrasound localization probe
FibroScan® Compact 530
Point-of-care solution for private practice or office-based settings
- LSM by VCTE®
- CAP
- SSM by VCTE®
- LHM™ compatibility
- FibroScan® Gateway compatibility
- myFibroScan compatibility
- Ultrasound localization probe
FibroScan® Expert 630
Point-of-care solution for high-volume hospital-based settings
- LSM by VCTE®
- CAP
- SSM by VCTE®
- LHM™ compatibility
- FibroScan® Gateway compatibility
- myFibroScan compatibility
- Ultrasound localization probe
FibroScan GO®
Point-of-care solution for primary care offices only
- LSM by VCTE®
- CAP
- SSM by VCTE®
- LHM™ compatibility
- FibroScan® Gateway compatibility
- myFibroScan compatibility
- Ultrasound localization probe
What is FibroScan®?
Not all liver scans are the same. Why settle for less?
FibroScan® is the original, non-invasive solution for assessing liver fibrosis and steatosis at the point-of-care in an exam that takes as little as four minutes.
Unlike other elastography tools, FibroScan® uniquely delivers proprietary biomarkers (LSM by VCTE®, CAP, and SSM by VCTE®), recognized by clinical guidelines, payer policies, and approved drug labeling.
Fast, quantitative, and standardized, FibroScan® provides the clarity clinicians need to detect risk earlier, guide informed decisions, and support ongoing management using measurements relied upon worldwide.
FibroScan® exams are widely covered by insurance and used across various specialties, including hepatology, gastroenterology, endocrinology, obesity medicine, and primary care.
What is VCTE®?
Validated. Proven. Exclusively FibroScan®. Not all transient elastography solutions are created equal.
Only one technology truly delivers the clinical confidence providers, payers, and researchers trust. VCTE® – only available through FibroScan® – is backed by 25 years of leadership with proven performance in liver health assessment.
Vibration-controlled transient elastography is not a generic “process”— it is a proprietary technology developed, patented, and exclusively commercialized by Echosens.
Across all major guidelines, FibroScan® is named directly and exclusively as the reference technology for non-invasive liver assessment. No competing device has contributed published evidence of comparable scale or quality to guideline development.
Backed by 25 Years of Clinical Excellence
FibroScan® biomarkers are cited in thousands of peer-reviewed studies and included in major international guidelines for MASLD/MASH and chronic liver disease.
FibroScan® is the most extensively studied solution in non-invasive liver assessment. Its proprietary biomarkers—LSM by VCTE®, CAP, and SSM by VCTE®—have been evaluated, reported, and cited in more than 6,270 peer-reviewed publications and nearly 250 international guidelines. Clinical validation of FibroScan® spans all major chronic liver diseases and patient morphologies, including populations where other non-invasive tests show reduced accuracy.
FibroScan® is directly cited in major U.S. and European clinical practice guidelines, including AASLD, AACE, AGA and EASL, as the preferred non-invasive test in patients with MASLD/MASH.
How Does the FibroScan® Exam Work?
Easy to perform, comfortable for patients, and designed for real-world workflows.
A FibroScan® examination is quick and painless. The exam is typically completed in four minutes or less, with results available immediately for point-of-care decision-making.
FibroScan® is designed to be easy to use—whether in a clinic, hospital, or high-volume practice. Any trained operator can perform the exam, with minimal learning curve and no imaging background required.
FibroScan® systems feature Guided VCTE®, a next-generation enhancement that provides real-time visual indicators to help guide operators to the optimal measurement location. Guided VCTE® supports consistent performance across all adult morphologies, including patients with BMI ≥ 35, ensuring quicker and more confident measurements in diverse populations.
What Support is Available?
When you adopt FibroScan®, you gain more than a device—you gain a long-term partner in metabolic liver health. FibroScan® customers receive ongoing support from dedicated clinical, service, and market access teams to help drive efficient implementation and sustained clinical success.
Our Clinical Application Specialists provide personalized onboarding, hands-on training, and workflow optimization guidance so that every team member—from physicians to clinical support staff—feels confident using FibroScan®.
To support skills development over time, Echosens offers a wide range of training resources, including:
- Echosens Academy, an e-learning platform with courses for FibroScan® operators and prescribers
- A clinical library, educational webinars, and user tutorials
To enhance the productivity of our customers, Echosens Technical Support you with a full range of services: technical support, probe calibrations, preventative maintenance, and curative maintenance.
This comprehensive ecosystem helps ensure optimal system performance, consistent examination quality, and a smooth experience for both clinicians and patients.
Trusted Across Specialties and Providers
FibroScan® supports risk assessment, staging, and monitoring of liver disease across primary care, endocrinology, gastroenterology, hepatology, and obesity medicine.
GASTROENTEROLOGY & HEPATOLOGY
In specialty clinics, FibroScan® is widely recognized as the benchmark for non-invasive liver assessment. It helps stage fibrosis, monitor disease progression, and assess treatment response across etiologies. With SSM by VCTE®, FibroScan® also offers a non-invasive solution with clinical validation for assessing portal hypertension.
ENDOCRINOLOGY & PRIMARY CARE
AASLD and AACE guidelines support the use of FibroScan® in primary care and endocrinology settings to assess liver fibrosis in at-risk patients. By offering point-of-care assessment, FibroScan® helps primary care and endocrinology providers identify liver disease earlier and streamline referrals with objective data.
BARIATRIC SURGERY & OBESITY MEDICINE
FibroScan® supports pre-operative risk assessment and postoperative follow-up for patients with obesity and MASLD/MASH. Its validated performance across high-BMI populations, combined with Guided VCTE® functionality, makes it a practical tool in bariatric and obesity medicine programs.
Our other solutions to assess liver health
Beyond FibroScan®, Echosens offers complementary solutions designed to extend liver disease assessment, support clinical decision-making and optimize patient follow-up across different care pathways.
*SSM is a marker for non-invasive evaluation of spleen stiffness which has been used in a clinical setting to assess portal hypertension and for variceal surveillance.
The FibroScan® device (Models: 502 Touch, 530 Compact, 430 Mini+, 230, and 630) is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE®) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP)* at 3.5 MHz. FibroScan® 630 Expert is also intended to measure spleen stiffness using VCTE® at 100 Hz shear wave frequency. FibroScan® liver stiffness measurements (LSM) by VCTE® may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan® CAP measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid for the clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided.*CAP refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP on S+ probe is only available with SmartExam capability.